鄰近類別 專利 [0/42] 期刊論文 [142/142] 類別統計 近3年內發表的文件:1(2.08%) 含全文筆數:30(62.50%) 文件下載次數統計 下載大於0次:30(100.00%) 下載大於100次:30(100.00%) 檔案下載總次數:17991(17.60%) 最後更新時間: 2024-12-11 15:11 上傳排行 資料載入中..... 下載排行 資料載入中..... 最近上傳 Discovery of novel AXL and MER inhi... The molecular mechanisms of EpCAM i... Discovery of clinical candidate DBP... Blockage of EGFR signaling repurpos... Clinical candidate DBPR112: A novel... Discovery of 2,4-diaminopyrimidines... Optimization of furanopyrimidine-ba... Optimization of quinazoline-based k... One-pot tandem oxidative dearomatiz... Toward the total syntheses of natur...

跳至: (選擇年份) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (選擇月份) January February March April May June July August September October November December 或輸入年份:

由新到舊排序 由最舊的開始

顯示項目1-25 / 48. (共2頁) 1 2 > >> 每頁顯示[10|25|50]項目

日期	題名	關聯
2023-10	Discovery of novel AXL and MER inhibitors as potential anticancer and immune modulator drugs	Annals of Oncology. 2023 Oct;34(Suppl. 2):S214.
2019-10	The molecular mechanisms of EpCAM in regulating tumor progression and development of anti-EpCAM antibodies for colon cancer diagnosis and therapy	Annals of Oncology. 2019 Oct;30(Suppl. 5):786.
2019-10	Discovery of clinical candidate DBPR112, a furanopyrimidine-based epidermal growth factor receptor inhibitor for the treatment of non-small cell lung cancer	Annals of Oncology. 2019 Oct;30(Suppl. 5):789.
2018-07	Clinical candidate DBPR112: A novel epidermal growth factor receptor inhibitor as a promising treatment for non-small cell lung cancer	Cancer Research. 2018 Jul;78(13, Suppl.):Meeting Abstract 4789.
2018-07	Blockage of EGFR signaling repurposes tumor metabolism through suppression of glycolysis and Kreb cycle in head and neck cancer	Cancer Research. 2018 Jul;78(13, Suppl.):Meeting Abstract 3944.
2018-01	Discovery and development of DBPR112 as a clinical candidate: A novel EGFR inhibitor for non-small cell lung cancer	Cancer Science. 2018 Jan;109(Suppl. 1):739.
2017-04	Toward the total syntheses of natural products containing trans-decalin skeleton from masked o-benzoquinone	Abstracts of Papers of the American Chemical Society. 2017 Apr;253:Meeting Abstract 516.
2017-04	Discovery of BPR1K871-a quinazoline based multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation	Abstracts of Papers of the American Chemical Society. 2017 Apr;253:Meeting Abstract 482.
2017-04	One-pot tandem oxidative dearomatization/ 4+3 cycloaddition: Masked o-benzoquinone with diaza-oxyallyl cation	Abstracts of Papers of the American Chemical Society. 2017 Apr;253:Meeting Abstract 185.
2015-08	BPR2P001S0, a Coumarin derivative, induced cell cycle arrest in A549 through inhibiting PDPK1 activity	Cancer Research. 2015 Aug;75:Abstract number 1754.
2015-08	Optimization of furanopyrimidine-based kinase inhibitors: Identification of a BTK kinase inhibitor for the treatment of B cell lymphoma	Abstracts of Papers of the American Chemical Society. 2015 Aug;250:Meeting Abstract 180.
2015-08	Discovery of 2,4-diaminopyrimidines bearing a unique pharmacophore as anaplastic lymphoma kinase inhibitors	Abstracts of Papers of the American Chemical Society. 2015 Aug;250:Meeting Abstract 182.
2015-08	Optimization of quinazoline-based kinase inhibitors: Identification of a dual FLT3/AURKA kinase inhibitor for the treatment of acute myeloid leukemia	Abstracts of Papers of the American Chemical Society. 2015 Aug;250:Meeting Abstract 490.
2014-11	Discovery of multiple kinases inhibitors, DBPR114, as the novel anti-cancer agent	European Journal of Cancer. 2014 Nov;50(Suppl. 6):92-93.
2014-11	CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors	European Journal of Cancer. 2014 Nov;50(Suppl. 6):19-20.
2014-10	Optimization of 5,6-fused pyrimidine-based kinase inhibitors by computer-aided drug design for the treatment of AML	Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 2530.
2014-10	Novel irreversible EGFR tyrosine kinase inhibitor, DBPR112, as a therapeutic candidate for lung adenocarcinoma	Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 1756.
2014-03	Efficient virtual screening using ligand efficiency based approach	Abstracts of Papers - American Chemical Society. 2014 Mar;247:Article number 55-MEDI.
2014-03	DBPR112, a potent and selective EGFR kinase inhibitor in preclinical study	Abstracts of Papers - American Chemical Society. 2014 Mar;247:Article number 315-MEDI.
2013-11	Peptide-mediated liposomal doxorubicin enhances drug delivery efficiency and therapeutic efficacy in lung cancer animal models	Journal of Thoracic Oncology. 2013 Nov;8(Suppl. 2):S779.
2013-11	A development drug candidate targeting EGFR kinase for lung cancer: DBPR112	Journal of Thoracic Oncology. 2013 Nov;8(Suppl. 2):S779-S780.
2013-04-07	BPR000K, a novel Aurora kinase inhibitor	Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 300-MEDI.
2013-04-07	Kinase-focused library: Design and synthesis of pyrimidines derivatives bearing amino substituents using high throughput parallel synthesis	Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 298-MEDI
2013-04-07	3D-QSAR assisted drug design: Identification of a potent quinazoline based Aurora kinase inhibitor	Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 87-MEDI.
2013-04-07	Development drug candidate targeting EGFR kinase: DBPR112	Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 299-MEDI.

顯示項目1-25 / 48. (共2頁) 1 2 > >> 每頁顯示[10|25|50]項目